Thus, new therapies with novel mechanisms of action that are also tolerable are needed for third-line treatment and beyond, particularly for patients with relapsed and/or refractory multiple myeloma who have disease that is refractory to standard-of-care agents including IMiDs, proteasome inhibitors, and anti-CD38 antibodies. This evidence concerns the gene CD38 and AL amyloidosis.